A large proportion of caregivers with children and adolescents diagnosed with attention-deficit/hyperactivity-disorder (ADHD) perceived that the burden of illness remained high even if the children are on current prescription drug therapy, according to a poster presented at the 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders in Washington, DC.
A large proportion of caregivers with children and adolescents diagnosed with attention-deficit/hyperactivity-disorder (ADHD) perceived that the burden of illness remained high even if the children are on current prescription drug therapy, according to a poster presented at the 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD) in Washington, DC.
However, the burden was perceived to be greatest among those whose children were receiving multiple medications, rather than those managed with once-daily, long-acting medications.
Recruited through patient panels, potential participants completed a screener questionnaire; they were invited to participate in the survey if they were aged at least 18 years, and cared for a child or adolescent aged 6—17 years with ADHD who had been stable on their current stimulant medication for at least 6 months.
Of 2571 respondents to the screener questionnaire, 1823 were terminated and did not take the online, 20-minute survey.
Three hundred caregivers (mean age of children, 13 years) receiving stimulant medications completed the survey.
Long- and short-acting stimulant monotherapy was received by 120 individuals and 90 individuals, respectively, and the remaining 90 individuals received multiple therapies.
There were 100 individuals in each age group (6—11, 12–14, and 15–17 years).
ADHD burden was quantified using a 5-point Likert scale that ranged from 1 (least severe) to 5 (most severe). Respondents were stratified by their child’s current treatment regimen: short-acting or long-acting monotherapy, or multiple medications.
Regardless of current medication, 43% of caregivers reported that their children experienced a significant impact of ADHD on daily activities (ie, responses were within the 2 most severe Likert categories).
Caregivers felt that ADHD had a greater impact on daily activities during the school week (47%) than during the weekend (29%).
The greatest burden fell during after-school activities/afternoon homework, (45%) followed by early morning (42%) and during evening homework/leisure time (41%).
During a typical school week, only 6% of caregivers felt that their child’s medication did not wear off during the day. But 39% reported that medication was most likely to wear off during the period of afterschool activities/afternoon homework.
Proportions of caregivers reporting a high impact of ADHD on their child’s relationships with teachers, friends/classmates, and parents/primary caregivers were qualitatively greater for the 6—11 years age group (41%, 37%, and 34%, respectively) than older age groups (12–14 years: 31%, 31%, and 33%, respectively; 15–17 years: 33%, 36%, and 32%, respectively).
Overall, caregivers reported ADHD burden was highest in children and adolescents receiving multiple therapies (51%), followed by those receiving short-acting (46%) or long-acting (36%) stimulants alone.
More than 40% of caregivers reported frequently feeling overwhelmed and exhausted, feeling stressed, and raising their voice more than they would like. Caregivers reported that their downtime was more frequently affected by their child or adolescent’s ADHD, than any other daily activity.
ADHD frequently affected the emotions and activities of more caregivers of those receiving multiple therapies than of those receiving monotherapy, and of caregivers of those aged 6—11 years of age more than the other 2 age groups.
The study had 2 main limitations—participant recruitment through patient panels may have introduced selection bias, and information reported by caregivers may have been subject to recall bias.
Reference
Robertson B, Khachatryan A, Andreini M, et al. Caregiver survey of the burden of disease in children and adolescents with attention deficit/hyperactivity disorder. Presented at the 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders; Washington, DC; January 12-14, 2018. Poster 37.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Pediatric Alopecia Areata Risks and Disparities Vary by Race and Ethnicity
October 30th 2024Alopecia areata is more prevalent in Hispanic, Asian/Pacific Islander, and Black children than in non-Hispanic White children, with some Asian subgroups having a higher risk compared with those of Chinese ethnicity.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Studies Highlight Heavy Burden on Caregivers of Patients With DMD
October 28th 2024Caregivers of both adults and children with Duchenne muscular dystrophy (DMD) face significant disruptions to their work productivity and personal lives, underscoring the need for better treatments and support systems.
Read More